Professor Gerhard Wolber leads the Molecular Drug Design research group at the Institute of Pharmacy , Freie Universitaet Berlin. His work focuses on computational approaches to drug discovery, with expertise in G-protein coupled receptors (GPCRs) , cytochrome P450 enzymes , Toll-like receptors , and viral protease inhibitors . He supervises a team of 13 PhD candidates 3 researchers 2 Master's students engaged in projects ranging from calcium channel blockers to CYP enzyme modulators for cancer therapy. Recent publications highlight his lab's contributions to pan-coronavirus drug discovery, TLR8 antagonism, and calcium channel inhibition. The team employs advanced methodologies including Molecular dynamics simulations Fragment-based de novo design Bayesian neural networks DFT calculations 3D pharmacophore modeling to bridge computational predictions with experimental validation. Notable projects include Virtual screening for TREM2-targeted glioblastoma therapeutics Allosteric communication path analysis via MDPath Immune checkpoint inhibitors for cancer immunotherapy Biased GPCR ligand development demonstrating a multidisciplinary approach to contemporary drug design challenges.
جستجوی استاد راهنمای دانشگاهی
برای مسیر پژوهشیتان، استاد راهنما، استاد دانشگاه و پژوهشگر مناسب را پیدا کنید و با آنها ارتباط بگیرید.
نمایش ۱-۱۵ از ۱۹ استاد راهنما
اطلاعات پروفایلها از صفحات عمومی دانشگاهها گرفته شده و ممکن است بهروز نباشد.
Tore B. Stage is a Professor and Research Leader at the Institute for Health Services Research (Clinical Pharmacology, Pharmacy and Environmental Medicine) at the University of Southern Denmark. His research focuses on individual variability in drug response, particularly drug interactions and pharmacogenetics, utilizing both in vitro models and clinical trials. Primary research areas: Pharmacogenetics Chemotherapy-Induced Peripheral Neuropathy Pharmacokinetic Modeling Drug Transport Mechanisms Key publications include mechanistic studies of neurotoxicity in cancer patients and translational models bridging in vitro and clinical findings. His work spans immunosuppressants, anticoagulants, and chemotherapeutic agents. Major scientific awards: Lundbeckfondens Talentpris (2017) DFF-Research Talent (2015) ISSX Poster Award (2017) Presidential Trainee Award (2016) Jason Morrow Trainee Award (2016) He supervises PhD students, including Mortensen, C. (2020-2022), on projects exploring chemotherapy-induced neuropathy mechanisms.
Luca Dellafiora is an Associate Professor at the Department of Food and Pharmaceutical Sciences, University of Parma, specializing in Food Chemistry (SSD CHIM/07-B). He leads international mobility coordination for the Master's Degree in Human Nutrition Sciences and manages internship programs. His research focuses on hybrid in silico/in vitro approaches to assess chemical risks and benefits in foods, particularly xenobiotics and mycotoxins. Education PhD in Food Science and Technology (2015), University of Parma Master's in Molecular Biology (2011), University of Parma Bachelor's in Biology (2008), University of Parma Research Interests Prof. Dellafiora investigates chemical and chemico-toxicological aspects of food compounds using computational and experimental methods. Key areas include mycotoxin metabolism , bioactive compound interactions , endocrine disruption , and food risk assessment . His work addresses detoxification strategies and masked mycotoxin analysis. Recent publications highlight trends in in silico modeling for toxin-receptor interactions, foodborne pathogen adhesion , and molecular mechanisms of contaminants . Articles span computational toxicology, mycotoxin research, and food safety innovations. Coordinates Telephone: 902073 Office: Science Park Area 17/A, Chemical Building Email: luca.dellafiora@unipr.it
Mingxing Tengمشاهده پروفایل
استادیار
Mingxing Teng is an Assistant Professor at Baylor College of Medicine, holding dual appointments in the Department of Pathology & Immunology and the Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology. He is also a member of the Dan L Duncan Comprehensive Cancer Center. Teng's research focuses on chemical biology and medicinal chemistry, with an emphasis on developing novel drug candidates targeting cancer and other diseases. His lab employs interdisciplinary approaches, including synthetic chemistry, molecular biology, and pharmacology, to design innovative therapies. Education includes a PhD from the Shanghai Institute of Organic Chemistry (2015) and postdoctoral training at Baylor College of Medicine (2018–2022) and Dana-Farber Cancer Institute/Harvard Medical School (2022–present). His work spans protein degradation mechanisms, kinase inhibitors, and targeted therapies. Key research areas include degrader drug development, enzyme activation, and molecular glue technologies. Teng has secured grants such as the CPRIT Scholar Award ($2M) and has published extensively in top-tier journals like Science , Cell Chemical Biology , and Angewandte Chemie .
- Drug Metabolism
- Pharmacogenetics
- Pharmacology
- +۵ مورد دیگر
Rheem Totah is Professor of Medicinal Chemistry and Associate Dean for Research and Graduate Programs at the University of Washington School of Pharmacy, with additional affiliations at the Plein Center for Aging. Her leadership spans the Department of Medicinal Chemistry, Office of Research, and multiple institutional centers including the CHOICE Institute and WE-REACH commercialization hub. Her educational foundation includes a B.S. (Honors) in Chemistry from Birzeit University (Palestine, 1995), followed by Master's (2000) and Ph.D. (2002) degrees in Medicinal Chemistry from the University of Kansas, all earned with honors. Dr. Totah's research program investigates prescription drug side effects in cardiac, skeletal muscle, and bone tissues through the lens of drug-endogenous substrate interactions and pharmacogenetics . Her lab pioneers work on cytochrome P450-mediated arachidonic acid metabolism and thiol methyltransferases like METTL7A/B, with specific focus on hydrogen sulfide methylation pathways. This research directly informs safer drug development by elucidating chemical mechanisms of toxicity. Analysis of her 15 most recent publications reveals dominant themes in drug-drug interactions (particularly with thiopurines and CYP inhibitors), pregnancy-induced pharmacokinetic changes , and cardioprotective oxylipin mechanisms . Her work consistently bridges basic enzymology with clinical applications in cardiovascular disease, diabetes, and renal carcinoma. As an active mentor, Dr. Totah advises students across training levels including TL-1 translational research fellow Christi, dental school-bound Justin, and METTL7B researcher Ben. Her lab operates within the University of Washington's robust research infrastructure including the Mass Spectrometry Center and EDGE Institute of Translational Health Sciences. The Totah Lab maintains a clear mission to elucidate tissue protection mechanisms through cytochrome P450 and methyltransferase pathways, with current projects investigating CYP2J2-QT interval relationships, pregnancy metabolome dynamics, and renal cell carcinoma therapeutics. Their recent discovery of METTL7B as the long-sought thiol methyltransferase represents a cornerstone finding with implications for captopril metabolism and hydrogen sulfide signaling.
Aik Jiang Lauمشاهده پروفایل
دانشیار
Aik Jiang Lau is an Associate Professor at the College of Pharmacy, Dalhousie University, specializing in Functional Pharmacogenetics, Epigenetics, and Drug Metabolism. His research bridges pharmacokinetics and pharmacodynamics to advance personalized pharmacotherapy. BSc (Honours) in Pharmacy, National University of Singapore PhD in Pharmaceutical Sciences, National University of Singapore Postdoctoral Fellowship in Pharmaceutical Sciences and Pharmacology, University of British Columbia His work focuses on genetic and non-genetic factors (e.g., drugs, food, microbiota) regulating drug metabolism and adverse reactions. Key areas include Aldehyde Oxidase Inhibition, Sulfotransferase Enzymology, and Steroid Receptor Pharmacology. From 2016–2022, his publications highlight interactions between drugs, nutraceuticals, and enzymes like CYP3A, SULT2A1, and PXR. Recent studies explore links between steroid hormones and cancer-related cognitive impairment. Postdoctoral Scientist Award - American Society for Pharmacology and Experimental Therapeutics (2012) Emil A. Pfitzer Postdoctoral Award - Society of Toxicology (2012) Best Presentation Award - International Society for the Study of Xenobiotics (2011) Dr. Lau's research team investigates mechanisms to improve drug efficacy and safety, with support from academic and institutional grants. He collaborates with international teams and supervises research trainees in pharmacogenomics and drug metabolism studies.
Trine Meldgaard Lund serves as an Associate Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. Her research focuses on optimizing pharmacotherapy and clinical trial designs through advanced pharmacometric modeling. With 85 research outputs and active collaborations across multiple countries, she maintains a significant international research presence. Her primary research domain centers on Population PKPD modelling and Pharmacometrics, specifically characterizing pharmacokinetic-pharmacodynamic relationships to identify sources of drug response variability. Key projects include fixed-dose combination development, model-based dose finding, PK meta-modeling of morphine, and investigating CYP enzyme differences in pediatric populations. Her work demonstrates strong translational impact through clinical pain trials and therapeutic drug monitoring applications. Lund's research portfolio shows consistent output in high-impact journals, with recent 2025 publications spanning nephrology, oncology, geriatric pharmacology, and cannabinoid therapeutics. Her work frequently addresses methodological challenges in clinical trial design and demonstrates particular expertise in modeling complex drug interactions and age-related pharmacokinetic variability. The collaborative nature of her research is evident through extensive co-authorship networks across Scandinavian institutions. As an educator, Lund teaches Pharmacokinetics and Pharmacodynamics across multiple courses including Basic Pharmacology, Principles of Pharmacology, and Organ-related Pharmacology. She also leads specialized elective courses and PhD-level instruction through the MIND program. Her academic leadership extends to organizing 9 significant professional activities including symposia on precision medicine, clinical trial design, and therapeutic drug monitoring for major Danish pharmacological societies.
- Medicinal Chemistry
- Drug Design
- DNA Targeting
- +۳ مورد دیگر
Mark Searcey is a Professor and Chair of Medicinal Chemistry at the University of East Anglia (UEA), part of the School of Chemistry, Pharmacy and Pharmacology. He has held leadership roles including Pro Vice Chancellor for Science (2019–2024) and Head of Pharmacy and Chemistry Schools. His academic journey includes positions at the Scripps Research Institute and University College Dublin, with a PhD from Hatfield Polytechnic (1989) and BSc from Loughborough University (1985). Research focuses on targeting DNA and protein-protein interactions for therapeutics, including Holliday junction binding, PPI inhibitors, and natural product-inspired drugs. Key projects involve duocarmycin-based prodrugs, gold nanoparticle therapies, and Peptide Directed Ligand Design for flat protein surfaces. His lab is equipped for solid/solution-phase synthesis and explores antibiotic and cancer therapies. He supervises students and leads projects funded by EPSRC, The Big C Appeal, and others. Notable collaborations include work on Nrf2/Keap1 interactions and P2X4 receptor modulation. The Searcey Lab is based at Norwich Research Park, with ongoing PhD opportunities in medicinal chemistry.
Kim G. Adcock is a Tenured Professor of Pediatrics in the School of Medicine and Associate Professor of Pharmacy Practice in the School of Pharmacy at the University of Mississippi Medical Center (UMC). She serves as Director of Pediatric Clinical Research within the Department of Pediatrics. Her academic roles include faculty positions since 2002, with prior experience at Louisiana State University and the University of North Carolina. Education: PharmD, University of Mississippi (1996) Pharmacy Practice Residency, UNC Hospitals (1997) Pediatric Specialty Residency, UNC Hospitals (1998) Associate in Science, East Central Community College (1992) Research Interests: Dr. Adcock focuses on pediatric pharmacology, clinical research methodologies, and cystic fibrosis (CF) management. Her work includes pharmacokinetic studies of pediatric medications, CF treatment protocols, and genetic modifiers of CF-related conditions. She leads NIH-funded studies and collaborates on international trials addressing CF exacerbations, antibiotic efficacy, and pediatric GERD management. Grants & Funding: Over 70 extramural and intramural grants, including studies on CF therapies (e.g., lumacaftor/ivacaftor), antibiotic regimens for Pseudomonas aeruginosa, and pediatric drug safety. Key sponsors include NIH, Vertex Pharmaceuticals, Gilead Sciences, and the Cystic Fibrosis Foundation. Awards: 2010 Research Day Poster Competition 2nd Place (UMC) 2003 Pediatrics Research Award (UMC) Phi Kappa Phi Honor Society Labs/Teams: Directs pediatric clinical research programs, collaborates with the NIH-funded Pediatric Pharmacology Research Unit, and participates in the Cystic Fibrosis Therapeutics Development Network.
Natallia Strushkevich is an Assistant Professor at Skolkovo Institute of Science and Technology (Skoltech), where she leads a research group at the Center for Molecular and Cellular Biology. Her work focuses on understanding redox-active proteins in humans and mycobacteria, with particular emphasis on the cytochrome P450 (CYP) enzyme family and their role in drug metabolism and tuberculosis pathogenesis. Dr. Strushkevich's research program investigates how CYP enzymes function in both human drug metabolism and in Mycobacterium tuberculosis. Her laboratory employs complex structural and functional studies to identify natural substrates and develop selective inhibitors of CYP enzymes. In humans, these enzymes metabolize endogenous compounds and drugs while catalyzing critical reactions in cholesterol, vitamin D3, eicosanoids, and steroid hormone biosynthesis. For M. tuberculosis, most CYP functions remain unknown, presenting significant research opportunities for novel tuberculosis treatments. Analysis of Dr. Strushkevich's recent publications reveals a strong methodological focus on X-ray crystallography combined with biochemical and electrochemical techniques. Her work spans structural biology of redox complexes, ligand binding dynamics, and substrate specificity studies, with particular emphasis on how experimental conditions (like glycerol presence) affect structural interpretations crucial for drug design. Dr. Strushkevich's research is supported by multiple grants from Russian funding agencies including the Ministry of Science and Higher Education of the Russian Federation (projects 075-00337-20-03 and 075-15-2021-1354), the Russian Foundation for Basic Research (project 122030100168-2), and Moscow Institute of Physics and Technology (project 075-15-2021-684). Her collaborative work involves researchers across multiple institutions specializing in structural biology and mycobacterial research. Dr. Strushkevich leads a multidisciplinary research group that combines X-ray crystallography, biochemical assays, electrochemical characterization, and molecular dynamics simulations to study protein structure-function relationships in redox systems. Her work on CYP-ferredoxin complexes and ligand binding mechanisms provides critical insights for developing new antitubercular drugs targeting these essential bacterial enzymes.
Gunnar Boysenمشاهده پروفایل
دانشیار
- Environmental Health
- Toxicology
- Metabolomics
- +۴ مورد دیگر
Gunnar Boysen, Ph.D. is an Associate Professor at the University of Arkansas for Medical Sciences (UAMS), affiliated with the Fay W. Boozman College of Public Health and the Department of Environmental and Occupational Health. His research focuses on understanding how chemical exposures interact with nutritional and lifestyle factors to influence health outcomes, particularly through DNA/protein adducts and metabolomics approaches. Education: Ph.D. in Chemistry (2002), University of Kaiserslautern (Germany) and University of Minnesota Cancer Center M.S. in Biology (1996), University of Kaiserslautern and German Cancer Research Center Postdoctoral Fellow (2005), University of North Carolina at Chapel Hill Research Interests: Dr. Boysen investigates metabolic reprogramming in cancer metastases, carcinogen metabolism pathways, and exposure biomarkers using advanced mass spectrometry. Key themes include: Chemical exposure effects on diet/physical activity Glutathione synthesis and radiation sensitivity Nanopore sequencing for DNA/RNA modifications Environmental toxin health impacts (e.g., 1,3-butadiene) Key Contributions: His work bridges toxicology and precision medicine, with notable studies on glutaminase inhibitors for cancer treatment (e.g., CB-839), biomarker development for butadiene exposure, and mechanistic insights into styrene/CYP2E1 interactions. Teaching: Teaches courses in environmental exposure assessment, toxicology, and occupational health. Lab/Teams: Leads research on metabolomic profiling of lung tumors, drug bioactivation studies, and environmental health risk assessment methodologies.
Lokman AYAZ is a Professor in the Department of Biochemistry at Trakya University's Faculty of Pharmacy. He holds a Doctoral degree (2011) and has held academic positions including Assistant Professor (2012), Associate Professor (2015), and Professor (2020). His research focuses on microRNA expression in diseases like cancer, oxidative stress, and pharmacological interventions. Notable works include studies on miRNA biomarkers in preeclampsia and lung cancer, as well as anti-VEGF therapies for retinopathy. Education: B.Sc. (2001), M.Sc. (2005), Ph.D. (2011). Research spans molecular biology, genetic polymorphisms, and drug responses. Over 100 peer-reviewed articles and conference presentations highlight his expertise in biomarker discovery and therapeutic targets. Key contributions include investigating microRNA roles in cancer diagnostics, oxidative stress mechanisms in cellular injury, and stem cell applications in tissue repair. His work bridges basic research with clinical applications in oncology, ophthalmology, and cardiovascular medicine. Grants and collaborations include studies on CYP enzyme polymorphisms in drug efficacy and ROS signaling in ischemia-reperfusion injury. Active in academic service, he has reviewed for journals like Molecular Biology Reports.
Michael Murray is an Honorary Professor at the University of Sydney's Sydney Pharmacy School and Discipline of Pharmacology within the School of Medical Sciences. He holds a Bachelor of Pharmacy (First Class Honours) and PhD from the University of Sydney, followed by postdoctoral research at Cornell University. His career includes NHMRC Research Fellowships (1987–1998) and leadership roles in toxicology and pharmacology societies. Education: BPharm (Hons), PhD, DSc (University of Sydney) Professional Roles: Editor for Toxicology and Applied Pharmacology and Xenobiotica Research focuses on anticancer drug design, cytochrome P450 regulation, and drug metabolism. Key projects include developing omega-3 fatty acid derivatives for cancer therapy and studying drug resistance mechanisms. Awards include the 2009 Innovation Award for anti-cancer drug research. Recent publications emphasize mitochondrial targeting agents, Ginkgo biloba’s antioxidant effects, and hepatitis C drug interactions. Collaborations span institutions like UNSW and the Sydney Medical School.
Thomas Charles Pochapsky is a Professor of Chemistry and Biochemistry in the Department of Chemistry at Brandeis University and an Affiliated Faculty member at the Rosenstiel Basic Medical Sciences Research Center. His research focuses on cytochrome P450 enzymes (CYPs), particularly their roles in drug metabolism and enzyme catalysis. His research interests include: Structure and function of cytochrome P450 enzymes Substrate selectivity and regioselective oxidation mechanisms Design of selective CYP inhibitors for therapeutic applications Application of nuclear magnetic resonance (NMR) spectroscopy in enzymology Integration of site-directed mutagenesis, enzyme assays, and organic synthesis in biochemical research Although no recent publications are listed in the provided text, his work centers on advancing the mechanistic understanding of CYPs and developing safer, more effective inhibitors for diseases such as cancer, tuberculosis, fungal infections, and nicotine addiction. Notable scientific awards and honors include: Richard A. Glenn Award for Coal Chemistry, ACS (1981) Fuson Award for Excellence in Organic Graduate Research, UIUC (1985) Michael L. Walzer '56 Award for Teaching, Brandeis University (1992) Camille and Henry Dreyfus Teacher-Scholar Award (1993–1995) Pochapsky is recognized for both his scholarly contributions and excellence in teaching. He mentors students in biochemistry and chemical biology, though specific advisees are not listed. His research has been supported by competitive grants, including the Dreyfus Teacher-Scholar Award. He is actively involved in the academic and research community at Brandeis, particularly through the Rosenstiel Center, where he conducts interdisciplinary work in basic medical sciences. His laboratory at the Rosenstiel Basic Medical Sciences Research Center integrates biophysical, biochemical, and synthetic approaches to study enzyme function and design novel inhibitors, contributing to both fundamental science and translational applications.
Pradeepraj Durairajمشاهده پروفایل
پژوهشگر ارشد
Pradeepraj Durairaj is a Postdoctoral Fellow at the Ramamoorthy Lab, Department of Chemical and Biomedical Engineering, Florida A&M University and Florida State University. His research focuses on cytochrome P450 enzymes, quorum sensing inhibition, biocatalysis, and biomedical engineering applications. Research Interests Enzymology of cytochrome P450s in human and fungal systems Development of quorum sensing inhibitors for antimicrobial applications Biomanufacturing of extracellular vesicles and lipidomics analysis Drug discovery for neurodegenerative diseases (e.g., Alzheimer's) Use of microbial cell factories for metabolic engineering Key Article Trends His recent publications emphasize biochemical approaches to anticancer agents (2025), bioreactor-based biomanufacturing of organoid-derived vesicles (2025), and neurological implications of brain CYP enzymes (2025). Earlier works (2011–2024) span fungal CYP biocatalysis, biofilm inhibition, and human drug metabolism platforms.